Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: Implications for the antiproliferative effects of antiestrogens

Cancer Research

Volumn 62, Issue 11, 2002, Pages 3126-3131

  Carroll, Jason S ^a   Swarbrick, Alexander ^a   Musgrove, Elizabeth A ^a   Sutherland, Robert L ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ANTISENSE OLIGONUCLEOTIDE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; ESTROGEN; FULVESTRANT; PROTEIN P21;

ARTICLE; BREAST CANCER; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN MCF 7; COMPLEX FORMATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTO ONCOGENE;

BREAST NEOPLASMS; CDC2-CDC28 KINASES; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN D1; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 0036606633     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Tamoxifen for early breast cancer: An overview of the randomised trials
2. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in the model of human breast cancer
3. Basic guide to the mechanisms of antiestrogen action
4. A potent specific pure antiestrogen with clinical potential
5. Response to a specific antioestrogen (IC1182780) in tamoxifen-resistant breast cancer
6. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence
7. Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells
8. Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation
9. 1-phase progression
10. New functional activities for the p21 family of CDK inhibitors
11. 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2
12. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells
13. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution
14. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry
15. c-Myc target genes involved in cell growth, apoptosis and metabolism
16. Overexpression of Mad transcription factor inhibits proliferation of cultured human hepatocellular carcinoma cells along with tumor formation in immunodeficient animals
17. Antisense c-myc retroviral vector suppresses established human prostate cancer
18. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer
19. Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells
20. Retroviruses and cancer genes
21. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination
22. Growth factor, steroid and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression
23. Differential effects of retinoids and antiestrogens on cell cycle progression and cell cycle regulatory genes in human breast cancer cells
24. Physicochemical properties of phosphorothioate oligodeoxynucleotides
25. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism
26. Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line
27. Kip1 for restriction point control of the fibroblast cell cycle
28. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion
29. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor β-induced cell-cycle arrest
30. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor
31. Regulation of c-myc transcription and mRNA abundance by serum growth factors and cell contact
32. c-myc protein expression in untransformed fibroblasts
33. 1 transition genes
34. Myc oncogenes and human neoplastic disease
35. A combination treatment of c-myc antisense DNA with all-trans-retinoic acid inhibits cell proliferation by downregulating c-myc expression in small cell lung cancer
36. Antisense oligodeoxynucleotide against c-myc mRNA induces differentiation of human hepatocellular carcinoma cells
37. The MYC protein activates transcription of the α-prothymosin gene
38. Myc represses the p21 (WAF1/CIP1) promoter and interacts with Sp1/Sp3
39. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation
40. Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle
41. Repression of cyclin D1: A novel function of MYC
42. An alternative pathway for gene regulation by Myc
43. Inducible regulatory elements in the human cyclin D1 promoter
44. Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes
45. Mutual requirement of Cdk4 and Myc in malignant transformation: Evidence for cyclin D1/Cdk4 and p16INK4A as upstream regulators of Myc
46. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells
47. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay
48. Reversible tumorigenesis by MYC in hematopoietic lineages
49. Reversible activation of c-Myc in skin: Induction of a complex neoplastic phenotype by a single oncogenic lesion